Medicus Pharma (NASDAQ:MDCX) Releases Earnings Results, Misses Estimates By $4.96 EPS

Medicus Pharma (NASDAQ:MDCX) released its quarterly earnings results on Friday. The company reported ($11.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.68) by ($4.96), FiscalAI reports.

Medicus Pharma Price Performance

Shares of Medicus Pharma stock opened at $1.87 on Friday. Medicus Pharma has a 1-year low of $1.70 and a 1-year high of $127.50. The company’s fifty day simple moving average is $6.14 and its 200-day simple moving average is $21.72. The stock has a market capitalization of $2.36 million, a PE ratio of -0.02 and a beta of 0.80.

Analyst Upgrades and Downgrades

A number of analysts recently commented on MDCX shares. Weiss Ratings upgraded Medicus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 30th. Wall Street Zen cut Medicus Pharma from a “sell” rating to a “strong sell” rating in a research report on Sunday. Finally, Alliance Global Partners reissued a “buy” rating on shares of Medicus Pharma in a research report on Monday, September 14th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $450.00.

About Medicus Pharma

Medicus Pharma Ltd. (NASDAQ:MDCX) is a life sciences company focused on acquiring, developing and commercializing pharmaceutical and medical products. The company seeks to identify therapies and healthcare technologies with potential for commercialization and works to advance them through regulatory, clinical and market-development processes.

Medicus Pharma’s activities are centered on specialty healthcare markets, including pharmaceutical and medical products designed to address unmet patient and provider needs.